Published in Presse Med on April 20, 1996
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46
Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet (1999) 3.14
Chromosome 9p-linked families with frontotemporal dementia associated with motor neuron disease. Neurology (2009) 2.46
APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry (2011) 2.31
Acute renal failure associated with combined gentamicin and cephalothin therapy. Br Med J (1973) 2.10
Valosin-containing protein gene mutations: clinical and neuropathologic features. Neurology (2006) 2.00
High frequency of potentially pathogenic SORL1 mutations in autosomal dominant early-onset Alzheimer disease. Mol Psychiatry (2012) 1.84
Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest (1979) 1.76
Usefulness of transcranial color-coded sonography in the diagnosis of cerebral vasospasm. Stroke (1999) 1.67
Variations in the APP gene promoter region and risk of Alzheimer disease. Neurology (2007) 1.64
Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. J Med Genet (2005) 1.60
Pediatric cerebral aneurysms. J Neurosurg (2001) 1.57
Giant cervical epidural veins after lumbar puncture in a case of intracranial hypotension. AJNR Am J Neuroradiol (2000) 1.55
Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. Hum Mol Genet (1995) 1.55
Penetration of newer cephalosporins into cerebrospinal fluid. Rev Infect Dis (1989) 1.49
Brain spect perfusion of frontotemporal dementia associated with motor neuron disease. Neurology (2007) 1.41
[Celioscopic cholecystectomy. 2 cases of infectious complications]. Presse Med (1994) 1.40
Adult onset Still's disease and pregnancy. J Rheumatol (1993) 1.39
Pharmacokinetics of temocillin (BRL 17421) in subjects with normal and impaired renal function. J Antimicrob Chemother (1983) 1.34
Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. Am J Hum Genet (1997) 1.27
Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism. Hum Mol Genet (1998) 1.27
Identification of three novel mutations (E196K, V203I, E211Q) in the prion protein gene (PRNP) in inherited prion diseases with Creutzfeldt-Jakob disease phenotype. Hum Mutat (2000) 1.27
Ofloxacin pharmacokinetics in renal failure. Antimicrob Agents Chemother (1987) 1.27
Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions. Eur J Immunol (1997) 1.22
Pharmacokinetics of cefoxitin sodium in normal subjects and in uraemic patients. J Antimicrob Chemother (1978) 1.21
Dementia with prominent frontotemporal features associated with L113P presenilin 1 mutation. Neurology (2000) 1.20
Genome-wide haplotype association study identifies the FRMD4A gene as a risk locus for Alzheimer's disease. Mol Psychiatry (2012) 1.20
Is presentation of bacteremia in the elderly the same as in younger patients? Am J Med (1996) 1.19
In vivo and in vitro activation and expansion of gammadelta T cells during Listeria monocytogenes infection in humans. Infect Immun (1997) 1.17
Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat (1999) 1.16
The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J Neurol (1996) 1.15
The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Rev Infect Dis (1983) 1.15
Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob Agents Chemother (1984) 1.13
Treatment of gram-negative bacillary meningitis: role of the new cephalosporin antibiotics. Rev Infect Dis (1983) 1.12
Supercontinuum generation system for optical coherence tomography based on tapered photonic crystal fibre. Opt Express (2006) 1.12
Pharmacokinetics of norfloxacin in renal failure. J Antimicrob Chemother (1984) 1.10
Apolipoprotein E epsilon4 allele and familial aggregation of Alzheimer disease. Arch Neurol (1998) 1.09
Detection of adenovirus in the waters of the Seine River estuary by nested-PCR. Mol Cell Probes (1998) 1.08
Taenia crassiceps invasive cysticercosis: a new human pathogen in acquired immunodeficiency syndrome? Am J Surg Pathol (1998) 1.06
Outcome in 43 patients with distal anterior cerebral artery aneurysms. Stroke (1997) 1.06
Sulfinpyrazone kinetics after intravenous and oral administration. Clin Pharmacol Ther (1979) 1.05
Fusobacterium nucleatum hepatic abscess with pylephlebitis associated with idiopathic CD4(+) T lymphocytopenia. Clin Infect Dis (2001) 1.02
[Treatment of anuria with furosemide]. Nouv Presse Med (1972) 1.00
Pharmacokinetics of moxalactam in subjects with normal and impaired renal function. Antimicrob Agents Chemother (1981) 0.99
Oropharyngeal dysphagia in amyotrophic lateral sclerosis alters quality of life. J Oral Rehabil (2012) 0.99
Efficacy of pefloxacin-fosfomycin in experimental endocarditis caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1988) 0.98
Pharmacokinetics of cefotaxime in subjects with normal and impaired renal function. J Antimicrob Chemother (1980) 0.96
Midsagittal MR measurements of the corpus callosum in healthy subjects and diseased patients: a prospective survey. AJNR Am J Neuroradiol (1993) 0.96
Pharmacokinetics of azlocillin in subjects with normal and impaired renal function. Antimicrob Agents Chemother (1980) 0.96
Comparative pharmacokinetics of lividomycin, amikacin and sisomicin in normal subjects and in uraemic patients. J Antimicrob Chemother (1976) 0.96
Clinical imaging and neuropathological correlations in an unusual case of cerebrotendinous xanthomatosis. Clin Neuropathol (2010) 0.96
Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur J Clin Pharmacol (1992) 0.95
Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis (1995) 0.95
Vigilance troubles in Parkinson's disease: a subjective and objective polysomnographic study. Sleep Med (2006) 0.95
A large pedigree with early-onset Alzheimer's disease: clinical, neuropathologic, and genetic characterization. Neurology (1995) 0.94
Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency. Chemotherapy (1979) 0.94
Epsilon sarcoglycan mutations and phenotype in French patients with myoclonic syndromes. J Med Genet (2005) 0.94
The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. Genomics (1995) 0.94
Hepatosplenic gamma/delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q. Am J Surg Pathol (1997) 0.94
Group R streptococci: wild boars as a second reservoir. Scand J Infect Dis (1985) 0.93
Pharmacokinetics of aminoglycosides in subjects with normal and impaired renal function. Antibiot Chemother (1971) (1978) 0.93
[Rheumatologial manifestations of bacterial endocarditis]. Rev Rhum Mal Osteoartic (1974) 0.93
Concentrations of cefotaxime and the desacetyl metabolite in serum and CSF of patients with meningitis. J Antimicrob Chemother (1984) 0.92
Triple combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a highly penicillin-and glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis (1993) 0.92
Measurement of voice onset time in dysarthric patients: methodological considerations. Folia Phoniatr Logop (2001) 0.91
Pharmacokinetics of dibekacin in normal subjects and in patients with renal failure. J Antimicrob Chemother (1980) 0.90
A novel presenilin 1 mutation resulting in familial Alzheimer's disease with an onset age of 29 years. Neuroreport (1996) 0.90
Lomefloxacin pharmacokinetics in subjects with normal and impaired renal function. Antimicrob Agents Chemother (1990) 0.90
Extracellular protease activity of different Pseudomonas strains: dependence of proteolytic activity on culture conditions. J Appl Microbiol (2005) 0.89
Intrafamilial diversity of phenotype associated with app duplication. Neurology (2008) 0.89
Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother (1992) 0.89
[Antibiotic audit]. Nouv Presse Med (1980) 0.89
Pharmacokinetics of netilmicin in the presence of normal or impaired renal function. Antimicrob Agents Chemother (1978) 0.89
The pharmacokinetics of ofloxacin in healthy adult male volunteers. Eur J Clin Pharmacol (1987) 0.89
Tentorial edge traumatic aneurysm of the superior cerebellar artery. Case report. J Neurosurg (1997) 0.88
A 12-kDa protein of Mycobacterium tuberculosis protects mice against experimental autoimmune encephalomyelitis. Protection in the absence of shared T cell epitopes with encephalitogenic proteins. J Immunol (1995) 0.88
Role of the O-phosphoserine clusters in the interaction of the bovine milk alpha s1-, beta-, kappa-caseins and the PP3 component with immobilized iron (III) ions. Biochim Biophys Acta (1997) 0.88
Cefoxitin concentrations in the cerebrospinal fluids of patients with meningitis. Antimicrob Agents Chemother (1980) 0.88
De novo presenilin 1 mutations are rare in clinically sporadic, early onset Alzheimer's disease cases. French Alzheimer's Disease Study Group. J Med Genet (1998) 0.88
Pharmacokinetics of habekacin in patients with renal insufficiency. Antimicrob Agents Chemother (1987) 0.87
Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases. QJM (2013) 0.87
Effects of bilateral subthalamic stimulation on sleep in Parkinson's disease. J Neurol (2004) 0.87
Severe attacks of familial hemiplegic migraine, childhood epilepsy and ATP1A2 mutation. Cephalalgia (2008) 0.87
An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang (2008) 0.86
Anatomy of executive deficit following ruptured anterior communicating artery aneurysm. Eur J Neurol (2009) 0.86
Morphological and molecular changes in the inner hair cell region of the rat cochlea after amikacin treatment. J Neurocytol (2000) 0.86
Treatment of acute hypercalcemia with furosemide. Curr Ther Res Clin Exp (1973) 0.86
Submental sensitive transcutaneous electrical stimulation (SSTES) at home in neurogenic oropharyngeal dysphagia: a pilot study. Ann Phys Rehabil Med (2011) 0.86
Metronidazole kinetics in patients with acute renal failure on dialysis: a cumulative study. Clin Pharmacol Ther (1984) 0.85
Effects of two oral erythromycin ethylsuccinate formulations on the motility of the small intestine in human beings. Antimicrob Agents Chemother (1996) 0.85
Characterization of atypical cells in the juvenile rat organ of corti after aminoglycoside ototoxicity. J Comp Neurol (1998) 0.84
No founder effect in three novel Alzheimer's disease families with APP 717 Val-->Ile mutation. Clerget-darpoux. French Alzheimer's Disease Study Group. J Med Genet (1996) 0.84
Pharmacokinetics of quinolones in renal insufficiency. J Antimicrob Chemother (1990) 0.84
Dysarthria and orofacial apraxia in corticobasal degeneration. Mov Disord (2000) 0.84
The impaired in vitro production of interleukin-2 in HIV infection is negatively correlated to the number of circulating CD4+DR+ T cells and is reversed by allowing T cells to rest in culture: arguments for in vivo CD4+ T cell activation. Clin Immunol Immunopathol (1993) 0.83